$0.87 EPS Expected for Eagle Pharmaceuticals Inc (NASDAQ:EGRX) This Quarter

Wall Street analysts predict that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will report $0.87 earnings per share for the current quarter, Zacks reports. Two analysts have provided estimates for Eagle Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.93 and the lowest estimate coming in at $0.80. Eagle Pharmaceuticals reported earnings per share of $1.18 in the same quarter last year, which would suggest a negative year over year growth rate of 26.3%. The firm is scheduled to announce its next quarterly earnings results on Thursday, November 7th.

On average, analysts expect that Eagle Pharmaceuticals will report full year earnings of $3.64 per share for the current year, with EPS estimates ranging from $3.41 to $3.95. For the next financial year, analysts forecast that the business will report earnings of $4.16 per share, with EPS estimates ranging from $3.10 to $5.26. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $0.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.17. The company had revenue of $56.70 million during the quarter, compared to analysts’ expectations of $53.61 million. Eagle Pharmaceuticals had a return on equity of 24.10% and a net margin of 19.79%. Eagle Pharmaceuticals’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.99 EPS.



Several equities analysts have recently weighed in on the company. BidaskClub upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, August 10th. Mizuho restated a “hold” rating and issued a $50.00 price objective on shares of Eagle Pharmaceuticals in a report on Wednesday, April 24th. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $66.00 price objective for the company in a report on Wednesday, August 14th. Cantor Fitzgerald restated a “hold” rating and issued a $58.00 price objective on shares of Eagle Pharmaceuticals in a report on Tuesday, May 7th. Finally, ValuEngine upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $58.80.

Shares of NASDAQ EGRX traded down $0.65 during mid-day trading on Thursday, hitting $58.28. The company had a trading volume of 7,701 shares, compared to its average volume of 140,561. The company has a market capitalization of $793.50 million, a PE ratio of 28.01 and a beta of 1.44. The firm has a 50-day simple moving average of $55.67 and a two-hundred day simple moving average of $51.14. The company has a current ratio of 3.59, a quick ratio of 3.36 and a debt-to-equity ratio of 0.21. Eagle Pharmaceuticals has a one year low of $36.03 and a one year high of $82.33.

A number of institutional investors have recently bought and sold shares of the stock. PNC Financial Services Group Inc. grew its position in shares of Eagle Pharmaceuticals by 156.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 642 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 392 shares during the period. Financial Gravity Wealth Inc. purchased a new position in Eagle Pharmaceuticals in the second quarter worth about $33,000. First Quadrant L P CA purchased a new position in Eagle Pharmaceuticals in the second quarter worth about $34,000. NumerixS Investment Technologies Inc purchased a new position in Eagle Pharmaceuticals in the second quarter worth about $39,000. Finally, Bank of Montreal Can raised its holdings in Eagle Pharmaceuticals by 395.0% in the second quarter. Bank of Montreal Can now owns 1,277 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 1,019 shares during the last quarter. Institutional investors and hedge funds own 98.37% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

Read More: How do analysts define an oversold condition?

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.